Tabla S1 de una pantalla CRISPR in vivo identifica que SNRPC promueve la progresión del cáncer de mama triple negativo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Table S1 from An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression2024
2. 2Table S2 from An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression2024
3. 3Table S2 from An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression2024
4. 4Table S8 from An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression2024
5. 5Table S8 from An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression2024